Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
238.83
+0.17 (0.07%)
May 11, 2026, 11:43 AM EDT - Market open
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 14 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $283.79, which forecasts a 18.83% increase in the stock price over the next year. The lowest target is $250 and the highest is $345.
Price Target: $283.79 (+18.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 9 | 10 | 10 | 10 | 10 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 16 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $342 → $345 | Buy | Maintains | $342 → $345 | +44.45% | May 11, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $330 → $326 | Buy | Maintains | $330 → $326 | +36.50% | May 8, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $262 → $292 | Strong Buy | Maintains | $262 → $292 | +22.26% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $273 | Buy | Reiterates | $273 | +14.31% | Apr 9, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $252 → $290 | Strong Buy | Initiates | $252 → $290 | +21.43% | Mar 16, 2026 |
Financial Forecast
Revenue This Year
1.40B
from 720.13M
Increased by 94.27%
Revenue Next Year
2.03B
from 1.40B
Increased by 44.96%
EPS This Year
4.27
from -3.76
EPS Next Year
10.21
from 4.27
Increased by 139.32%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6B | 2.5B | ||||||
| Avg | 1.4B | 2.0B | ||||||
| Low | 1.3B | 1.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 116.2% | 77.8% | ||||||
| Avg | 94.3% | 45.0% | ||||||
| Low | 73.6% | 15.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.34 | 17.84 | ||||||
| Avg | 4.27 | 10.21 | ||||||
| Low | 0.95 | 5.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 318.2% | ||||||
| Avg | - | 139.3% | ||||||
| Low | - | 17.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.